Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma

CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION

Joan Bladé, Diana Samson, Donna Reece et al. · British Journal of Haematology · 1998 · 1.5K citations

Medicine, Hematology, Oncology +17

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.

James R. Berenson, Alan Lichtenstein, Lisa A. Porter et al. · Journal of Clinical Oncology · 1998 · 653 citations

Medicine, Pharmacology, Pharmacotherapy +14

Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma

Volker Kunzmann, Eva Bauer, Juliane Feurle et al. · Blood · 2000 · 625 citations

Life Sciences, Cell Biology, Immunology +11

Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.

S. Boissier, Mercedes Ferreras, Olivier Peyruchaud et al. · PubMed · 2000 · 573 citations

Medicine, Oncology, Pharmacology +17

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases

James R. Berenson, Lee S. Rosen, Anthony Howell et al. · Cancer · 2001 · 532 citations · Full text

Medicine, Oncology, Radiation Oncology +17